Physician profile
Steven Lee Martin
NPI 1417917568
$356,284.32
in general payments reported to CMS, 2019-2025
18 companies · $282K in 2025
The $282K reported for 2025 was more than what 99% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,486 · 2021: $14K · 2022: $16K · 2023: $4,172 · 2024: $20K · 2025: $282K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $277K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $12K · Food and Beverage: $2,402 · Consulting Fee: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $277,066.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,220.00 |
| Travel and Lodging | $11,789.66 |
| Food and Beverage | $2,402.31 |
| Consulting Fee | $2,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $351,149.08 | 2019-2025 | Arthrex |
| Peerless Surgical INC. | $4,706.61 | 2019-2025 | |
| Bioventus LLC | $78.16 | 2021-2024 | Durolane, Durolane, Exogen Ultrasound Bone Healing System |
| Polynovo North America LLC | $47.83 | 2024 | Novosorb Btm |
| Linvatec Corporation | $33.32 | 2022-2024 | Linvatec Shoulder Arthroscopy, Biobrace 23mm, Livatec Knee Preservation System |
| Smith+Nephew, INC. | $32.84 | 2021 | |
| Day One Biopharmaceuticals | $32.11 | 2025 | Ojemda |
| Davol INC. | $27.81 | 2025 | Arista |
| Csl Behring | $27.14 | 2025 | Hemgenix |
| Abbott Laboratories | $24.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.59 | 2023 | |
| Convatec INC. | $16.33 | 2021 | |
| Avita Medical Americas, LLC | $15.19 | 2024 | |
| Pfizer INC. | $15.12 | 2019 | |
| Novo Nordisk INC | $14.93 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14.82 | 2021 | |
| Heraeus Medical, LLC. | $14.77 | 2024 | |
| Ferring Pharmaceuticals INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.